Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Drug Name | NKR-2 cells |
| Trade Name | |
| Synonyms | NKG2D CAR-T cells|CYAD-01|CYAD-101 |
| Drug Descriptions |
NKR-2 cells are T-lymphocytes engineered to express a chimeric antigen receptor consists of human natural killer receptor (NKG2D) and the human CD3 zeta signaling domain, which may results in anti-tumor immunity (J Clin Oncol 35, 2017 (suppl; abstr TPS3093), PMID: 29133316). |
| DrugClasses | |
| CAS Registry Number | NA |
| NCIT ID | C121536 |
| Therapy Name | Drugs | Efficacy Evidence | Clinical Trials |
|---|---|---|---|
| Fluorouracil + Irinotecan + Leucovorin + NKR-2 cells | Fluorouracil Irinotecan Leucovorin NKR-2 cells | 0 | 1 |
| Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin | Fluorouracil Leucovorin NKR-2 cells Oxaliplatin | 0 | 1 |
| Fluorouracil + Leucovorin + NKR-2 cells + Oxaliplatin + Pembrolizumab | Fluorouracil Leucovorin NKR-2 cells Oxaliplatin Pembrolizumab | 0 | 1 |
| NKR-2 cells | NKR-2 cells | 0 | 2 |